Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report

Carla Ripamonti, Chiara Ticozzi, Ernesto Zecca, Carlos H. Rodriguez, Franco De Conno

Research output: Contribution to journalArticle

Abstract

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

Original languageEnglish
Pages (from-to)413-415
Number of pages3
JournalTumori
Volume82
Issue number4
Publication statusPublished - Jul 1996

Keywords

  • cancer
  • continuous subcutaneous infusion
  • ketorolac tromethamine
  • neuropathic pain

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report'. Together they form a unique fingerprint.

  • Cite this